Molina Healthcare has been treading water for the past six months, recording a small loss of 3.6% while holding steady at $329.49.
Is now the time to buy MOH? Find out in our full research report, it’s free.
Founded in 1980 as a provider for underserved communities in Southern California, Molina Healthcare (NYSE:MOH) provides managed healthcare services primarily to low-income individuals through Medicaid, Medicare, and Marketplace insurance programs across 21 states.
A company’s long-term sales performance is one signal of its overall quality. Any business can have short-term success, but a top-tier one grows for years. Over the last five years, Molina Healthcare grew its sales at an impressive 19.3% compounded annual growth rate. Its growth surpassed the average healthcare company and shows its offerings resonate with customers.
Larger companies benefit from economies of scale, where fixed costs like infrastructure, technology, and administration are spread over a higher volume of goods or services, reducing the cost per unit. Scale can also lead to bargaining power with suppliers, greater brand recognition, and more investment firepower. A virtuous cycle can ensue if a scaled company plays its cards right.
With $40.65 billion in revenue over the past 12 months, Molina Healthcare boasts impressive economies of scale. It may not be as large as heavyweights such as UnitedHealth Group and The Cigna Group from a topline perspective, but its heft is still an important advantage in a healthcare industry that is heavily regulated, complex, and resource-intensive.
Revenue growth can be broken down into the number of customers and the average spend per customer. Both are important because an increasing customer base leads to more upselling opportunities while the revenue per customer shows how successful a company was in executing its upselling strategy.
Molina Healthcare’s total customers came in at 5.54 million in the latest quarter, and over the last two years, their count averaged 4.4% year-on-year growth. This performance slightly lagged the sector and suggests that increasing competition is causing challenges in landing new contracts.
Molina Healthcare’s positive characteristics outweigh the negatives, but at $329.49 per share (or 12.6× forward price-to-earnings), is now the right time to buy the stock? See for yourself in our in-depth research report, it’s free.
